Furthermore, the identification of key biomarkers such as LCN2, ELANE, CAMP, and CTSG not only enhances our understanding of MS mechanisms but also offers valuable insights for the development of diagnostic and therapeutic tools. This evidence concerns the gene LCN2 and myeloid sarcoma.